Marktanalyse - Post Operative Nausea And Vomiting - Pipeline Review, H2 2016

Global Markets Direct
12.2016
50 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Post Operative Nausea And Vomiting - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Operative Nausea And Vomiting - Pipeline Review, H2 2016, provides an overview of the Post Operative Nausea And Vomiting (Gastrointestinal) pipeline landscape.

Postoperative nausea and vomiting (PONV) is one of the commonest complaints following anaesthesia, and can result in morbidity like wound dehiscence, bleeding, pulmonary aspiration of gastric contents, fluid and electrolyte disturbances, delayed hospital discharge, unexpected hospital admission, and decreased patient satisfaction. The thorough understanding of the mechanism of nausea and vomiting and a careful assessment of risk factors provide a rationale for appropriate management of PONV. This multimodal PONV management approach includes use of: (i) multiple different antiemetic medications (double or triple combination antiemetic therapy acting at different neuroreceptor sites); (ii) less emetogenic anaesthesia techniques; (iii) adequate intravenous hydration; and (iv) adequate pain control.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Operative Nausea And Vomiting - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Post Operative Nausea And Vomiting (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Operative Nausea And Vomiting (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Post Operative Nausea And Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Unknown stages are 2, 1, 1 and 1 respectively.Post Operative Nausea And Vomiting.

Post Operative Nausea And Vomiting (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post Operative Nausea And Vomiting (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Post Operative Nausea And Vomiting (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post Operative Nausea And Vomiting (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post Operative Nausea And Vomiting (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post Operative Nausea And Vomiting (Gastrointestinal)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post Operative Nausea And Vomiting (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post Operative Nausea And Vomiting (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Post Operative Nausea And Vomiting Overview 6

Therapeutics Development 7

Pipeline Products for Post Operative Nausea And Vomiting - Overview 7

Post Operative Nausea And Vomiting - Therapeutics under Development by Companies 8

Post Operative Nausea And Vomiting - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Unknown Stage Products 11

Post Operative Nausea And Vomiting - Products under Development by Companies 12

Post Operative Nausea And Vomiting - Companies Involved in Therapeutics Development 13

Acacia Pharma Ltd 13

Camurus AB 14

GW Pharmaceuticals Plc 15

INSYS Therapeutics Inc 16

Suda Ltd 17

Post Operative Nausea And Vomiting - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Combination Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 27

(buprenorphine hydrochloride + granisetron hydrochloride) - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

amisulpride - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

nabiximols - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

ondansetron hydrochloride - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

ondansetron hydrochloride - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Post Operative Nausea And Vomiting - Dormant Projects 41

Post Operative Nausea And Vomiting - Discontinued Products 42

Post Operative Nausea And Vomiting - Product Development Milestones 43

Featured News & Press Releases 43

Aug 12, 2016: Positive Results From Pivotal Phase 3 Trial of BAREMSIS For The Treatment of PONV 43

Mar 21, 2016: Initiation of Second Pivotal Phase 3 Treatment Trial with BAREMSIS (APD421) in PONV 43

Jan 05, 2016: Positive Results From Second Pivotal Phase 3 Study Of BAREMSIS (APD421) In PONV 44

Apr 21, 2015: Phase 3 Combination Prophylaxis Study Initiated With APD421 In PONV 45

Oct 07, 2014: Acacia Pharma Announces Positive Phase 3 Results For APD421 in Post-Operative Nausea & Vomiting 46

Sep 17, 2013: Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting 46

May 28, 2012: Acacia Pharma Announces Positive Results For APD421 In Post-Operative Nausea & Vomiting 47

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50





List of Tables

Number of Products under Development for Post Operative Nausea And Vomiting, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Unknown Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Post Operative Nausea And Vomiting - Pipeline by Acacia Pharma Ltd, H2 2016 13

Post Operative Nausea And Vomiting - Pipeline by Camurus AB, H2 2016 14

Post Operative Nausea And Vomiting - Pipeline by GW Pharmaceuticals Plc, H2 2016 15

Post Operative Nausea And Vomiting - Pipeline by INSYS Therapeutics Inc, H2 2016 16

Post Operative Nausea And Vomiting - Pipeline by Suda Ltd, H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Assessment by Combination Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 26

Post Operative Nausea And Vomiting - Dormant Projects, H2 2016 41

Post Operative Nausea And Vomiting - Discontinued Products, H2 2016 42





List of Figures

Number of Products under Development for Post Operative Nausea And Vomiting, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 10

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Stage and Molecule Types, H2 2016 26

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus